PANTUMOR 1479-0009

222730

ANV600-001

PRIMROSE (D9970C00001)

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

RMC-6291-101

STX-721-101

D6900C00001

CA1201001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

KEYNOTE 158

A Phase 1/2 Study of BMS-986449 Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors



<ul class="wp-block-list">
<li>Code NKI: M23CAS</li>



<li>Code firma: CA1201001</li>



<li>Code clinicaltrials.gov: NCT05888831</li>
</ul>



Principal Investigator



Dr. G. Ruiter



Drugs 



BMS-986449 (HELIOS degrader) +/- nivolumab



<ul class="wp-block-list">
<li>NSCLC, TNBC &#8211; open</li>



<li>Prostate cancer, melanoma &#8211; closed</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.



Read more on <a href="https://clinicaltrials.gov/study/NCT05888831?term=CA1201001&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1">clinicaltrials</a><a href="https://www.clinicaltrials.gov/study/NCT05700656?term=Phase%20I%2FII%20study%20with%20galunisertib%20combined%20with%20capecitabine%20in%20patients%20%20with%20advanced%20chemotherapy%20resistant%20colorectal%20cancer%20with%20peritoneal%20%20metastases&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1">.gov</a>

CA1201001

Summary

This website uses cookies